@biopharma_cg It's interesting that in ph2 $MRK gefapixant showed ~20% PBO-adjusted cough reduction at 7.5 mg and 20 mg. 

But then in the two big ph3's the 15 mg dose failed. MRK hasn't yet published the actual numbers. 

Will be interesting to see how much efficacy declined. $BLU https://t.co/QpoAAlPrHj